miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype

Emerging evidence shows the crucial role of inflammation (particularly NF‐κB pathway) in the development and progression of myelofibrosis (MF), becoming a promising therapeutic target. Furthermore, tailoring treatment with currently available JAK inhibitors (such as ruxolitinib or fedratinib) does n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2024-07, Vol.99 (7), p.1326-1337
Hauptverfasser:	Cuenca‐Zamora, Ernesto José, Guijarro‐Carrillo, Pedro J., López‐Poveda, María J., Morales, María Luz, Lozano, María Luisa, Gonzalez‐Conejero, Rocío, Martínez, Constantino, Teruel‐Montoya, Raúl, Ferrer‐Marín, Francisca
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Animals Collagen (type I) Disease Models, Animal Fibrosis Hematopoiesis, Extramedullary - drug effects Hemopoiesis Hypoplasia Inflammation IRAK protein Janus kinase Janus kinase 2 Mice Mice, Knockout MicroRNAs - genetics Myelofibrosis NF-kappa B - metabolism Nitriles - pharmacology Nitriles - therapeutic use Osteosclerosis Phenotypes Primary Myelofibrosis - drug therapy Primary Myelofibrosis - genetics Pyrazoles - pharmacology Pyrazoles - therapeutic use Pyrimidines - pharmacology Pyrimidines - therapeutic use Signal Transduction - drug effects Therapeutic targets Thrombocytopenia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!